HomeROIV • NASDAQ
add
Roivant Sciences Ltd
$11.23
Makalipas ang Oras ng Trabaho:(0.089%)-0.0100
$11.22
Sarado: Hun 6, 5:20:00 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$11.20
Sakop ng araw
$11.11 - $11.44
Sakop ng taon
$8.73 - $13.06
Market cap
7.63B USD
Average na Volume
5.58M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 7.57M | -16.08% |
Gastos sa pagpapatakbo | 227.69M | 128.37% |
Net na kita | -206.48M | -36.63% |
Net profit margin | -2.73K | -62.81% |
Kita sa bawat share | -0.22 | 6.85% |
EBITDA | -357.00M | -95.25% |
Aktuwal na % ng binabayarang buwis | -24.29% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 4.89B | -24.76% |
Kabuuang asset | 5.44B | -24.72% |
Kabuuang sagutin | 249.74M | -67.73% |
Kabuuang equity | 5.19B | — |
Natitirang share | 679.81M | — |
Presyo para makapag-book | 1.66 | — |
Return on assets | -16.26% | — |
Return on capital | -16.71% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -206.48M | -36.63% |
Cash mula sa mga operasyon | -172.56M | -59.11% |
Cash mula sa pag-invest | 1.07B | 15,405.11% |
Cash mula sa financing | -177.15M | -443.01% |
Net change in cash | 723.99M | 636.25% |
Malayang cash flow | -15.51M | 81.83% |
Tungkol
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
CEO
Itinatag
Abr 7, 2014
Website
Mga Empleyado
750
